TP53 and neoplasm: Moreover, drugs that reactivate wild-type TP53 by inhibiting its interaction with human/mouse double minute 2 (MDM2/Mdm2 inhibitors), thereby inducing tumor cell apoptosis, have received considerable attention over the past two decades as a novel treatment strategy for both solid and hematolymphoid tumors (Konopleva et al., 2020).